HC Wainwright Issues Pessimistic Outlook for RVMD Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD) – Equities research analysts at HC Wainwright decreased their FY2025 earnings per share estimates for shares of Revolution Medicines in a research report issued to clients and investors on Thursday, November 6th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($5.60) per share for the year, down from their prior estimate of ($5.10). HC Wainwright has a “Buy” rating and a $73.00 price objective on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. HC Wainwright also issued estimates for Revolution Medicines’ Q4 2025 earnings at ($1.54) EPS, Q1 2026 earnings at ($1.54) EPS, Q2 2026 earnings at ($1.56) EPS, Q3 2026 earnings at ($1.59) EPS, Q4 2026 earnings at ($1.61) EPS and FY2026 earnings at ($6.30) EPS.

A number of other brokerages have also commented on RVMD. Wedbush boosted their price objective on shares of Revolution Medicines from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Needham & Company LLC lifted their price target on shares of Revolution Medicines from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Lifesci Capital initiated coverage on shares of Revolution Medicines in a research report on Monday, August 18th. They set an “outperform” rating and a $80.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a report on Wednesday, October 8th. Finally, Mizuho assumed coverage on Revolution Medicines in a research report on Tuesday, October 21st. They issued an “outperform” rating and a $90.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Revolution Medicines presently has a consensus rating of “Buy” and an average target price of $78.71.

Revolution Medicines Trading Up 2.2%

NASDAQ:RVMD opened at $64.08 on Monday. The company has a market cap of $12.39 billion, a P/E ratio of -12.39 and a beta of 1.25. Revolution Medicines has a twelve month low of $29.17 and a twelve month high of $64.26. The business has a 50 day moving average price of $49.61 and a two-hundred day moving average price of $42.40. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.22). During the same period last year, the company posted ($0.94) earnings per share.

Institutional Investors Weigh In On Revolution Medicines

A number of large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its position in Revolution Medicines by 45.1% during the third quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock worth $39,000 after purchasing an additional 260 shares during the period. CWM LLC raised its position in shares of Revolution Medicines by 171.3% in the second quarter. CWM LLC now owns 917 shares of the company’s stock valued at $34,000 after purchasing an additional 579 shares during the period. Banque Transatlantique SA acquired a new stake in shares of Revolution Medicines during the 1st quarter worth about $42,000. Quarry LP acquired a new stake in shares of Revolution Medicines during the 1st quarter worth about $50,000. Finally, Twin Tree Management LP bought a new stake in shares of Revolution Medicines during the 1st quarter worth about $58,000. Institutional investors own 94.34% of the company’s stock.

Insiders Place Their Bets

In related news, insider Lin Wei sold 2,160 shares of Revolution Medicines stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $45.82, for a total transaction of $98,971.20. Following the completion of the transaction, the insider owned 88,339 shares in the company, valued at approximately $4,047,692.98. This trade represents a 2.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Stephen Michael Kelsey sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $48.54, for a total value of $1,213,500.00. Following the transaction, the insider directly owned 284,047 shares in the company, valued at approximately $13,787,641.38. This trade represents a 8.09% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 188,033 shares of company stock worth $8,456,208 in the last three months. Insiders own 8.20% of the company’s stock.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.